Related references
Note: Only part of the references are listed.Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council
Bruce Strober et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study
Amy S. Paller et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Apremilast and psoriasis in the real world: A retrospective case series
Lauren Dozier et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Drug survival of apremilast in a real-world setting
Megumi Kishimoto et al.
JOURNAL OF DERMATOLOGY (2019)
Trial of Apremilast for Oral Ulcers in Behcet's Syndrome
Guelen Hatemi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics
Steven R. Feldman et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2019)
Drug survival of apremilast in patients treated for psoriasis in a real-world setting
Erica B. Lee et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial
Maurizio Cutolo et al.
JOURNAL OF RHEUMATOLOGY (2016)
Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naive patients with psoriasis
April W. Armstrong et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments
Nannie Bangsgaard et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2015)
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
C. Paul et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Emerging oral drugs for psoriasis
Tahmina Mahmood et al.
EXPERT OPINION ON EMERGING DRUGS (2015)
Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis
Arthur Kavanaugh et al.
JOURNAL OF RHEUMATOLOGY (2015)
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Apremilast mechanism of action and application to psoriasis and psoriatic arthritis
Peter Schafer
BIOCHEMICAL PHARMACOLOGY (2012)
The concept of psoriasis as a systemic inflammation: implications for disease management
K. Reich
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2012)
Guidelines of care for the management of psoriasis and psoriatic arthritis Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
Guidelines of care for the management of psoriasis and psoriatic arthritis - Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics
Alice Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study
P. Gisondi et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
Folate with methotrexate: big benefit, questionable cost
I. Brownell et al.
BRITISH JOURNAL OF DERMATOLOGY (2007)
Phosphodiesterase-4 as a therapeutic target
MD Houslay et al.
DRUG DISCOVERY TODAY (2005)
Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A
AC Zambon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Share Paper
